Cargando…

Cancer immunotherapy: Moving beyond checkpoint inhibition

Detalles Bibliográficos
Autor principal: Boes, Marianne
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6290967/
https://www.ncbi.nlm.nih.gov/pubmed/30564293
http://dx.doi.org/10.18632/oncotarget.26384
_version_ 1783380180202422272
author Boes, Marianne
author_facet Boes, Marianne
author_sort Boes, Marianne
collection PubMed
description
format Online
Article
Text
id pubmed-6290967
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Impact Journals LLC
record_format MEDLINE/PubMed
spelling pubmed-62909672018-12-18 Cancer immunotherapy: Moving beyond checkpoint inhibition Boes, Marianne Oncotarget Editorial Impact Journals LLC 2018-11-27 /pmc/articles/PMC6290967/ /pubmed/30564293 http://dx.doi.org/10.18632/oncotarget.26384 Text en Copyright: © 2018 Boes. http://creativecommons.org/licenses/by/3.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0/) 3.0 (CC BY 3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Editorial
Boes, Marianne
Cancer immunotherapy: Moving beyond checkpoint inhibition
title Cancer immunotherapy: Moving beyond checkpoint inhibition
title_full Cancer immunotherapy: Moving beyond checkpoint inhibition
title_fullStr Cancer immunotherapy: Moving beyond checkpoint inhibition
title_full_unstemmed Cancer immunotherapy: Moving beyond checkpoint inhibition
title_short Cancer immunotherapy: Moving beyond checkpoint inhibition
title_sort cancer immunotherapy: moving beyond checkpoint inhibition
topic Editorial
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6290967/
https://www.ncbi.nlm.nih.gov/pubmed/30564293
http://dx.doi.org/10.18632/oncotarget.26384
work_keys_str_mv AT boesmarianne cancerimmunotherapymovingbeyondcheckpointinhibition